Professionals 826 results
Capabilities 78 results
Industry
Practice Area
Employee Benefits & Executive Compensation
Practice Area
Experience 488 results
Experience
|April 27, 2026
Winston Represents Initial Purchasers in GABX Leasing’s $1 Billion Inaugural Senior Notes Offering
Experience
|April 6, 2026
MLBPI’s Licensing Fight Ends in Victory and Settlement with DraftKings
Experience
|April 2, 2026
Business Combination and Secured Financing of Keo World and Maha Capital AB
Insights & News 6,995 results
Client Alert
|April 30, 2026
|4 Min Read
SEC and CFTC Propose Changes to Reduce Form PF Reporting Burdens
On April 20, 2026, the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) (collectively, the Commissions) jointly proposed amendments to Form PF (the Proposal) that, if adopted, would significantly reduce reporting burdens for private fund advisers. The Proposal would largely unwind the comprehensive amendments to Form PF adopted in February 2024 (the 2024 Amendments) before the October 1, 2026 compliance date, primarily by increasing filing thresholds and eliminating or streamlining a number of reporting requirements.
Competition Corner
|April 29, 2026
|10+ Min Read
Recent settlements in DOJ antitrust enforcement actions have raised concerns on Capitol Hill and beyond about the adequacy of current safeguards governing the settlement of federal antitrust cases.
Capital Markets & Securities Law Watch
|April 27, 2026
|4 Min Read
SEC Grants Exemptive Relief for Shortened Equity Tender Offers
On April 16, 2026, the Securities and Exchange Commission’s (the SEC) Office of Mergers and Acquisitions in the Division of Corporation Finance (the Division) issued an exemptive order (the Order) permitting certain tender offers for equity securities to remain open for a minimum of 10 business days rather than the standard 20 business days, subject to strict conditions designed to preserve investor protections.
Other Results 73 results
Location
Site Content
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?


